Proteomics International Laboratories Ltd (ASX:PIQ) Launches Promarker®D Test to Combat Diabetic Kidney Disease in Australia
Product Launch and Rollout
Proteomics International Laboratories Ltd (ASX:PIQ) has launched Promarker®D, a predictive test for chronic kidney disease in type 2 diabetes patients. The test is now available to Australian healthcare professionals, with the initial rollout in Western Australia and the Northern Territory, before expanding nationwide.
Health Impact
Promarker®D can predict the onset of chronic kidney disease up to four years in advance, enabling earlier medical intervention. With over 1.3 million Australians living with diabetes and more than half at risk of kidney disease, the test aims to reduce kidney failure and dialysis incidences.
Global Expansion
The Australian launch serves as a foundation for global expansion, with plans to enter the USA and European markets. Proteomics International has opened a Reference Laboratory in California to support this growth.
Executive Comments
Managing Director Dr Richard Lipscombe stated, “We are excited to officially launch PromarkerD in Australia, particularly on World Kidney Day, which underscores the importance of early diagnosis and prevention. Diabetic kidney disease is a major public health challenge, and PromarkerD offers a highly innovative, accurate, and accessible way to identify those most at risk. By enabling proactive management, we aim to reduce the personal and financial costs associated with this life-threatening condition.”
Motley Fool contributor Aaron Shaw has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.